Medicine Description inhiglip 25mg
inhiglip 25mg tablets is a medication that operates by inhibiting the enzyme dipeptidyl peptidase-4 (DPP-4). DPP-4 is responsible for the breakdown of incretin hormones, which are released in response to food intake. By inhibiting this enzyme, alogliptin increases the levels of incretin hormones, leading to enhanced insulin secretion from pancreatic beta cells in a glucose-dependent manner. This action not only helps lower blood glucose levels after meals but also reduces glucagon levels, which decreases hepatic glucose production. This dual mechanism of action effectively contributes to better glycemic control in individuals with type II diabetes.
Indications and Uses of inhiglip 25mg tablets
- Management of type II diabetes mellitus
- Used in conjunction with diet and exercise to improve glycemic control
- Appropriate for patients not adequately controlled on other antidiabetic medications
Side Effects of inhiglip 25mg tablets
- Headache
- Nausea
- Diarrhea
- Upper respiratory tract infection
- Hypoglycemia (when used with other antidiabetic agents)
Storage and Handling
Store inhiglip 25mg tablets at room temperature, away from moisture and heat. Keep out of reach of children and do not use after the expiration date indicated on the package.
Patient Advice and Precautions
Patients should be advised to monitor their blood sugar levels regularly and report any significant changes to their healthcare provider. It is essential to maintain a balanced diet and engage in regular physical activity while on this medication. Inform healthcare providers of any other medications being taken to avoid potential interactions. Patients should also be aware of symptoms of hypoglycemia and know how to manage it effectively.